Recent Updates
Recently added Catalysts
SEER Positive Sentiment

Seer to Report Second Quarter 2023 Financial Results on August 8, 2023

Key Takeaway: Seer, Inc. has announced that it will report its financial results for the second quarter of 2023 on August 8, 2023. The results will be shared after market close, followed by a conference call webcasting at 1:30 p.m. Pacific Time. Seer is noted for its development of the Proteograph Product Suite, which enables deep proteomic analysis.
Price reaction · baseline $4.96 (2023-07-12 close) · hit after-hours · clean, no other SEER news in the window
day 0 close · peak
+4.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Seer is reporting financial results, indicating continued operational activity.
  • The company is developing innovative products in the proteomics field.
  • The Proteograph Product Suite provides efficient solutions for laboratories.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~65 mo
Minimal dilution risk
Lead asset
standardized turmeric root extract
Phase 1 · Cystic Fibrosis

Full Press Release Details

REDWOOD CITY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report financial results for the second quarter of 2023 after market close on Tuesday, August 8, 2023. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the event.
Seer is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph™ Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.

Frequently Asked Questions

When will Seer, Inc. report its Q2 2023 financial results?

Seer will report its Q2 2023 financial results on August 8, 2023, after market close.

Where can I watch the Seer conference call?

The conference call will be webcast live on Seer’s Investor section of their website.

What is Seer's Proteograph Product Suite?

Seer's Proteograph Product Suite is a solution for deep, unbiased proteomic analysis.

Is Seer’s Proteograph intended for diagnostic use?

No, Seer's Proteograph Product Suite is for research use only, not for diagnostics.

What features does the Proteograph workflow offer?

The Proteograph workflow is efficient, easy to use, and leverages common lab instruments.

Last updated: Jul 13, 2023